Aller au contenu principal
xMedica

NCT06056830ClinicalTrials.gov

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Phase 3383 participants recherchés34 sites3 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 31 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.

How this score is built
  • Enrolment25/40

    383 participants (target)

  • Site count18/25

    31 sites

  • Country count7/15

    3 countries

  • Planned duration8/10

    Planned over about 33 months

  • Sponsor scale2/10

    Clarity Pharmaceuticals Ltd has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Affections

  • Prostate Cancer
  • Prostatic Neoplasms

Éligibilité

Éligibilité
SexeHomme
Âges18 YearsAucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * At least 18 years of age. * Signed informed consent. * Untreated, histologically confirmed adenocarcinoma of the prostate. * High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA \>20 ng/mL). * Patients electing to undergo RP with PLND. Exclusion Criteria: * Administration of any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1. * Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components. * Patients with known predominant small cell or neuroendocrine PC.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionSans objet
Modèle d'interventionSINGLE_GROUP
Objectif principalDIAGNOSTIC
InsuNONE (0)
Recrutement383 participants recherchés

Promoteur et collaborateurs

  • Clarity Pharmaceuticals Ltd Promoteur

Groupes et interventions

  • 64Cu-SAR-bisPSMAEXPERIMENTAL

    200MBq 64Cu-SAR-bisPSMA.

Interventions

  • Médicament 64Cu-SAR-bisPSMA

    All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

Critères de jugement

  1. Critère de jugement principal

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases

    Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.

    Délai Up to 16 weeks

  2. Critère de jugement secondaire

    Safety and tolerability of 64Cu-SAR-bisPSMA

    Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA

    Délai Up to 16 weeks

  3. Critère de jugement secondaire

    Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers

    Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic

    Délai Up to 16 weeks

  4. Critère de jugement secondaire

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth

    Délai Up to 16 weeks

  5. Critère de jugement secondaire

    Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer

    Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth

    Délai Up to 16 weeks

  6. Critère de jugement secondaire

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching

    Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth

    Délai Up to 16 weeks

Dates

Dates
Date de début21 décembre 2023 (réelle)
Achèvement principal1 septembre 2026 (estimée)
Achèvement1 septembre 2026 (estimée)
Première publication28 septembre 2023 (réelle)
Dernière mise à jour11 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

34 sites sont en recrutement

Australia

Australia
ÉtablissementVilleÉtat ou régionStatut
Fiona Stanley HospitalMurdochWestern AustraliaEn recrutement
RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private HospitalNedlandsWestern AustraliaEn recrutement
St. Vincent's SydneySydneyNew South WalesEn recrutement
Princess Alexandra HospitalWoolloongabbaQueenslandEn recrutement

Puerto Rico

Puerto Rico
ÉtablissementVilleÉtat ou régionStatut
Pan American Center for Oncology Trials, LLC - CiudadelaSan JuanEn recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Albany Medical College, Department of UrologyAlbanyNew YorkEn recrutement
Urology Austin, PLLC - Research DepartmentAustinTexasEn recrutement
University of Alabama Birmingham HospitalBirminghamAlabamaEn recrutement
University of Texas Southwestern Medical CenterDallasTexasEn recrutement
Urology Clinics of North TexasDallasTexasEn recrutement
Duke University Medical CenterDurhamNorth CarolinaEn recrutement
NorthShore University Health System, Glenbrook HospitalGlenviewIllinoisEn recrutement
BAMF HealthGrand RapidsMichiganEn recrutement
Corewell HealthGrand RapidsMichiganEn recrutement
Indiana University School of MedicineIndianapolisIndianaEn recrutement
Mayo Clinic- JacksonvilleJacksonvilleFloridaEn recrutement
Arkansas Urology Research Center, LLCLittle RockArkansasEn recrutement
Greater Los Angeles VA Medical CenterLos AngelesCaliforniaEn recrutement
Urology Group of Southern CaliforniaLos AngelesCaliforniaEn recrutement
University of WisconsinMadisonWisconsinEn recrutement
Biogenix Molecular, LLCMiamiFloridaEn recrutement
Intermountain HealthMurrayUtahEn recrutement
Carolina Urologic Research CenterMyrtle BeachSouth CarolinaEn recrutement
Urology Associates of NashvilleNashvilleTennesseeEn recrutement
Mount Sinai Doctors Urology Faculty PracticeNew YorkNew YorkEn recrutement
XCancer Omaha LLCOmahaNebraskaEn recrutement
UC Irvine HealthOrangeCaliforniaEn recrutement
Mayo Clinic- PhoenixPhoenixArizonaEn recrutement
Mayo Clinic- RochesterRochesterMinnesotaEn recrutement
The Urology PlaceSan AntonioTexasEn recrutement
Oregon UrologySpringfieldOregonEn recrutement
Stanford University Medical CenterStanfordCaliforniaEn recrutement
Urologic SpecialistsTulsaOklahomaEn recrutement
Wichita Urology GroupWichitaKansasEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 11 septembre 2026

    Site ajouté

    3 sites added (34 total)

    3134